Vaxart (OTCMKTS:VXRT) Stock Price Crosses Above 200 Day Moving Average – Here’s Why

Vaxart, Inc. (OTCMKTS:VXRT) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.56 and traded as high as $0.69. Vaxart shares last traded at $0.68, with a volume of 168,499 shares traded.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of Vaxart to a “buy” rating in a research report on Friday, January 23rd.

Vaxart Stock Performance

The stock has a market cap of $164.54 million, a price-to-earnings ratio of 4.53 and a beta of 1.18. The firm’s 50-day simple moving average is $0.69 and its two-hundred day simple moving average is $0.56.

Vaxart (OTCMKTS:VXRT) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.02 earnings per share for the quarter, meeting the consensus estimate of $0.02. The firm had revenue of $39.23 million during the quarter, compared to analysts’ expectations of $50.50 million. Vaxart had a net margin of 14.51% and a return on equity of 61.43%.

Institutional Investors Weigh In On Vaxart

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. grew its position in shares of Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock worth $107,000 after buying an additional 34,075 shares during the period. Invesco Ltd. grew its position in shares of Vaxart by 93.1% during the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after buying an additional 70,568 shares during the period. Creative Planning acquired a new stake in shares of Vaxart during the 2nd quarter worth approximately $33,000. Goldman Sachs Group Inc. acquired a new stake in shares of Vaxart during the 1st quarter worth approximately $31,000. Finally, Jones Financial Companies Lllp grew its position in shares of Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after buying an additional 478,111 shares during the period. Institutional investors and hedge funds own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.